The high-risk abnormality del(17p) can be detected by fluorescence in situ hybridization on malignant plasma cells (PCs) and has an adverse prognostic impact in patients with multiple myeloma (MM). Patients with del(17p) have reduced overall survival (OS). Patients who acquire del(17p) later during the disease course are not well described. The disease characteristics at diagnosis predicting for acquired del(17p) and its overall impact on patient survival is not known. We compared 76 patients with MM who were negative for del(17p) at diagnosis and acquired it later with 152 control MM patients who did not acquire del(17p) at a comparable time point. Patients acquired del(17p) at a median of 35.6 months (range, 4.6-116.1 months) from diagnosis of MM after a median of 2 lines of therapy (range, 1-10 lines of therapy). When compared with controls, patients with acquired del(17p) had shorter median progression-free survival (PFS) (30.1 vs 23.0 months; P = .032) and OS (106.1 vs 68.2 months; P < .001) from diagnosis. After the detection of del(17p), the median PFS was 5.4 months and the median OS was 18.1 months. High lactate dehydrogenase level (odds ratio [OR], 3.69; 95% confidence interval [CI], 1.11-12.24) and presence of t(4;14) (OR, 2.66; 95% CI, 1.09-6.48) or any high-risk translocation (OR, 2.23; 95% CI, 1.00-4.95) at diagnosis predicted acquisition of del(17p). High PC proliferative rate predicted shorter OS from detection of del(17p) (hazard ratio, 2.28; 95% CI, 1.31-3.96; P = .004). Our study shows that acquisition of del(17p) is an important molecular event associated with reduction in OS in MM. Certain baseline factors may predict acquisition of del(17p). This needs validation in prospective data sets.

4th Department of Internal Medicine Hematology University Hospital Hradec Kralove Hradec Kralove Czech Republic; and

Department of Laboratory Medicine and Pathology Mayo Clinic Rochester MN

Division of Hematology Mayo Clinic Rochester MN

Zobrazit více v PubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30. PubMed

Kumar SK, Rajkumar SV. The multiple myelomas - current concepts in cytogenetic classification and therapy. Nat Rev Clin Oncol. 2018;15(7):409-421. PubMed

Kumar SK, Rajkumar V, Kyle RA, et al. . Multiple myeloma. Nat Rev Dis Primers. 2017;3(1):17046. PubMed

Lodé L, Eveillard M, Trichet V, et al. . Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica. 2010;95(11):1973-1976. PubMed PMC

Teoh PJ, Chung TH, Sebastian S, et al. . p53 haploinsufficiency and functional abnormalities in multiple myeloma. Leukemia. 2014;28(10):2066-2074. PubMed

Avet-Loiseau H, Attal M, Moreau P, et al. . Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood. 2007;109(8):3489-3495. PubMed

Avet-Loiseau H, Attal M, Campion L, et al. . Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol. 2012;30(16):1949-1952. PubMed

Kumar SK, Rajkumar SV, Dispenzieri A, et al. . Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516-2520. PubMed PMC

Ravi P, Kumar SK, Cerhan JR, et al. . Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J. 2018;8(3):26. PubMed PMC

Kumar SK, Dimopoulos MA, Kastritis E, et al. . Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31(11):2443-2448. PubMed

Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer. 2017;17(9):543-556. PubMed

Avet-Loiseau H, Li JY, Godon C, et al. . P53 deletion is not a frequent event in multiple myeloma. Br J Haematol. 1999;106(3):717-719. PubMed

Smith D, Stephenson C, Percy L, et al. . Cohort analysis of FISH testing of CD138(+) cells in relapsed multiple myeloma: implications for prognosis and choice of therapy. Br J Haematol. 2015;171(5):881-883. PubMed

Schultheis B, Krämer A, Willer A, Hegenbart U, Goldschmidt H, Hehlmann R. Analysis of p73 and p53 gene deletions in multiple myeloma. Leukemia. 1999;13(12):2099-2103. PubMed

Corre J, Cleynen A, Robiou du Pont S, et al. . Multiple myeloma clonal evolution in homogeneously treated patients. Leukemia. 2018;32(12):2636-2647. PubMed PMC

Chin M, Sive JI, Allen C, et al. . Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival. Blood Cancer J. 2017;7(9):e610. PubMed PMC

Kumar S, Paiva B, Anderson KC, et al. . International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328-e346. PubMed

Rajkumar SV, Harousseau JL, Durie B, et al. ; International Myeloma Workshop Consensus Panel 1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691-4695. PubMed PMC

Rajkumar SV, Richardson P, San Miguel JF. Guidelines for determination of the number of prior lines of therapy in multiple myeloma. Blood. 2015;126(7):921-922. PubMed

Fonseca R, Blood E, Rue M, et al. . Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101(11):4569-4575. PubMed

Kumar S, Rajkumar SV, Greipp PR, Witzig TE. Cell proliferation of myeloma plasma cells: comparison of the blood and marrow compartments. Am J Hematol. 2004;77(1):7-11. PubMed

Aljama MA, Sidiqi MH, Lakshman A, et al. . Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. Blood Adv. 2018;2(22):3149-3154. PubMed PMC

García-Sanz R, González-Fraile MI, Mateo G, et al. . Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients. Int J Cancer. 2004;112(5):884-889. PubMed

Morice WG, Hanson CA, Kumar S, Frederick LA, Lesnick CE, Greipp PR. Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders. Leukemia. 2007;21(9):2043-2046. PubMed

Lakshman A, Painuly U, Rajkumar SV, et al. . Natural history of multiple myeloma with de novo del(17p). Blood Cancer J. 2019;9(3):32. PubMed PMC

Chang H, Trieu Y, Qi X, Jiang NN, Xu W, Reece D. Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains. Leuk Res. 2011;35(1):95-98. PubMed

Chen MH, Qi CX, Saha MN, Chang H. p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide. Am J Clin Pathol. 2012;137(2):208-212. PubMed

Dimopoulos MA, Moreau P, Palumbo A, et al. ; ENDEAVOR Investigators. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27-38. PubMed

Avet-Loiseau H, Bahlis NJ, Chng WJ, et al. . Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood. 2017;130(24):2610-2618. PubMed

Greipp PR, Lust JA, O’Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood. 1993;81(12):3382-3387. PubMed

San Miguel JF, García-Sanz R, González M, et al. . A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood. 1995;85(2):448-455. PubMed

Steensma DP, Gertz MA, Greipp PR, et al. . A high bone marrow plasma cell labeling index in stable plateau–phase multiple myeloma is a marker for early disease progression and death. Blood. 2001;97(8):2522. PubMed

Sidiqi MH, Aljama MA, Jevremovic D, et al. . Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. Haematologica. 2018;103(7):1229-1234. PubMed PMC

Keats JJ, Chesi M, Egan JB, et al. . Clonal competition with alternating dominance in multiple myeloma. Blood. 2012;120(5):1067-1076. PubMed PMC

Merz M, Jauch A, Hielscher T, et al. . Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation. Haematologica. 2017;102(8):1432-1438. PubMed PMC

Keats JJ, Craig DW, Liang W, et al. . Interim analysis of the MMRF CoMMpass Trial, a longitudinal study in multiple myeloma relating clinical outcomes to genomic and immunophenotypic profiles [abstract]. Blood. 2013;122(21). Abstract 532.

Ross FM, Avet-Loiseau H, Ameye G, et al. ; European Myeloma Network. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica. 2012;97(8):1272-1277. PubMed PMC

Shah V, Johnson DC, Sherborne AL, et al. ; National Cancer Research Institute Haematology Clinical Studies Group. Subclonal TP53 copy number is associated with prognosis in multiple myeloma. Blood. 2018;132(23):2465-2469. PubMed PMC

Chavan SS, He J, Tytarenko R, et al. . Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker. Blood Cancer J. 2017;7(2):e535. PubMed PMC

Thanendrarajan S, Tian E, Qu P, et al. . The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Haematologica. 2017;102(9):e364-e367. PubMed PMC

Walker BA, Mavrommatis K, Wardell CP, et al. . A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019;33(1):159-170. PubMed PMC